Circ_001680 aggravates the malignant process of gastric carcinoma by targeting MAP2.

This study aims to explore the expression pattern and clinical significance of circ_001680 in gastric carcinoma (GC) process. Circ_001680 levels in 40 pairs of GC and paracancerous ones were detected by quantitative real-time polymerase chain reaction (qRT-PCR). The relationship between circ_001680 and GC clinicopathological parameters was analyzed. AGS and SGC-7901 cells were used for constructing circ_001680 knockdown models by shRNA transfection. Proliferative and metastatic abilities in GC cells with circ_001680 knockdown were examined by cell counting kit-8 (CCK-8) and transwell assay, respectively. Dual-Luciferase reporter assay was conducted to clarify the interaction between circ_001680 and MAP2. Their co-regulation on GC process was detected through rescue experiments. Circ_001680 was highly expressed in GC tissues and cell lines. High level of circ_001680 predicted high incidences of lymphatic and distant metastasis, and poor prognosis in GC patients. Knockdown of circ_001680 suppressed proliferative and metastatic abilities in AGS and SGC-7901 cells. MAP2 was the target gene binding circ_001680, which was lowly expressed in GC. In addition, MAP2 was negatively correlated to circ_001680. Knockdown of MAP2 could abolish the suppressed proliferative and metastatic abilities in GC cells with circ_001680 knockdown. Circ_001680 is highly expressed in GC tissues and closely related to metastasis and prognosis in GC patients, which promotes the proliferative and metastatic abilities in GC cells by negatively interacting with MAP2.

Citation

H-D Zhao, Y Ma, X-S Wu, J-J Cheng, Z-G Xia, C Kan, X-J Ding, W-D Chen, L-Z Zhang, X-Y Wang, Y Cai, S-Y Wang. Circ_001680 aggravates the malignant process of gastric carcinoma by targeting MAP2. European review for medical and pharmacological sciences. 2020 Jun;24(11):6072-6079

Mesh Tags

Substances

PMID: 32572922

search → result